Doniec, Z.; Olszanecka-Glinianowicz, M.; Hantulik, P.; Almgren-Rachtan, A.; Chudek, J.
The Efficacy, Tolerance and Acceptance of a New Fixed-Dose Salmeterol and Fluticasone Propionate Dry-Powder Inhaler—Salflumix Easyhaler® in COPD Patients in the Daily Clinical Practice. Appl. Sci. 2022, 12, 12142.
https://doi.org/10.3390/app122312142
AMA Style
Doniec Z, Olszanecka-Glinianowicz M, Hantulik P, Almgren-Rachtan A, Chudek J.
The Efficacy, Tolerance and Acceptance of a New Fixed-Dose Salmeterol and Fluticasone Propionate Dry-Powder Inhaler—Salflumix Easyhaler® in COPD Patients in the Daily Clinical Practice. Applied Sciences. 2022; 12(23):12142.
https://doi.org/10.3390/app122312142
Chicago/Turabian Style
Doniec, Zbigniew, Magdalena Olszanecka-Glinianowicz, Piotr Hantulik, Agnieszka Almgren-Rachtan, and Jerzy Chudek.
2022. "The Efficacy, Tolerance and Acceptance of a New Fixed-Dose Salmeterol and Fluticasone Propionate Dry-Powder Inhaler—Salflumix Easyhaler® in COPD Patients in the Daily Clinical Practice" Applied Sciences 12, no. 23: 12142.
https://doi.org/10.3390/app122312142
APA Style
Doniec, Z., Olszanecka-Glinianowicz, M., Hantulik, P., Almgren-Rachtan, A., & Chudek, J.
(2022). The Efficacy, Tolerance and Acceptance of a New Fixed-Dose Salmeterol and Fluticasone Propionate Dry-Powder Inhaler—Salflumix Easyhaler® in COPD Patients in the Daily Clinical Practice. Applied Sciences, 12(23), 12142.
https://doi.org/10.3390/app122312142
